Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State.

作者: Georgianne L. Arnold , Carlos A. Saavedra-Matiz , Patricia A. Galvin-Parton , Richard Erbe , Ellen DeVincentis

DOI: 10.1016/J.YMGME.2009.10.188

关键词:

摘要: Abstract Introduction: Medium chain acyl-CoA dehydrogenase (MCAD) deficiency is one of the most common inborn errors metabolism. Affected patients have impaired ability to break down medium fatty acids during fasting, and typically present in early years life with hypoketotic hypoglycemia, Reye syndrome-like symptoms, brain damage or death. The development newborn screening (NBS) for MCAD has greatly improved outcome, but some still appear at risk severe complications. We reviewed outcome identified by New York State NBS process identify biochemical genotypic markers which might predict outcome. Method: All eight follow-up centers contributed cases diagnosed screen, who received diagnostic care their clinic. Data included gender, age, birthweight, initial octanoylcarnitine level (C8) C8/C2 ratio, C8 hexanoylglycine, race/ethnicity, presence neonatal later symptoms. Results: 53 deficiency. More than quarter had a post-neonatal symptomatic admission (predominantly lethargy associated an intercurrent illness). No genotype was protective There relationship between ratio occurrence symptoms (7.3μmol/L asymptomatic vs. 19.1μmol/L symptomatic, p 30μmol/L; these infants high rate multiple episodes history sibling death from "SIDS", deletion, nonsense splice sites mutations. Infants having episode were more likely higher on predicted strongly affect protein function. In our ethnically diverse group patients, c.985A>G mutation rarely found non-Caucasians. Discussion: metabolite profile strong suggests that least neonates levels may be demonstrating increased susceptibility catabolic stress, merit additional precautions. Our data also suggest are carry mutations including homozygosity mutation, deletions, site reports significant hypoglycemia illness over even when medical intervention recommended (and not profoundly elevated) underscores importance continued vigilance prevent stressful fasting this disorder.

参考文章(11)
Leigh Waddell, Veronica Wiley, Kevin Carpenter, Bruce Bennetts, Lyn Angel, Brage S. Andresen, Bridget Wilcken, Medium-chain acyl-CoA dehydrogenase deficiency : Genotype-biochemical phenotype correlations Molecular Genetics and Metabolism. ,vol. 87, pp. 32- 39 ,(2006) , 10.1016/J.YMGME.2005.09.020
Michelle Kompare, William B. Rizzo, Mitochondrial fatty-acid oxidation disorders. Seminars in Pediatric Neurology. ,vol. 15, pp. 140- 149 ,(2008) , 10.1016/J.SPEN.2008.05.008
H.-W. Hsu, T. H. Zytkovicz, A. M. Comeau, A. W. Strauss, D. Marsden, V. E. Shih, G. F. Grady, R. B. Eaton, Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. ,vol. 121, ,(2008) , 10.1542/PEDS.2007-1993
Brage Storstein Andresen, Steve F Dobrowolski, Linda O'Reilly, Joseph Muenzer, Shawn E McCandless, Dianne M Frazier, Szabolcs Udvari, Peter Bross, Inga Knudsen, Rick Banas, Donald H Chace, Paul Engel, Edwin W Naylor, Niels Gregersen, None, Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. American Journal of Human Genetics. ,vol. 68, pp. 1408- 1418 ,(2001) , 10.1086/320602
William J. Rhead, Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective. Journal of Inherited Metabolic Disease. ,vol. 29, pp. 370- 377 ,(2006) , 10.1007/S10545-006-0292-1
Thomas H Zytkovicz, Eileen F Fitzgerald, Deborah Marsden, Cecilia A Larson, Vivian E Shih, Donna M Johnson, Arnold W Strauss, Anne Marie Comeau, Roger B Eaton, George F Grady, Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clinical Chemistry. ,vol. 47, pp. 1945- 1955 ,(2001) , 10.1093/CLINCHEM/47.11.1945
Matthew J. Nichols, Carlos A. Saavedra-Matiz, Kenneth A. Pass, Michele Caggana, Novel mutations causing medium chain acyl-CoA dehydrogenase deficiency: under-representation of the common c.985 A > G mutation in the New York state population American Journal of Medical Genetics Part A. ,vol. 146, pp. 610- 619 ,(2008) , 10.1002/AJMG.A.32192
Scott D Grosse, Muin J Khoury, Carol L Greene, Krista S Crider, Rodney J Pollitt, The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: An update Genetics in Medicine. ,vol. 8, pp. 205- 212 ,(2006) , 10.1097/01.GIM.0000204472.25153.8D
Bridget Wilcken, Marion Haas, Pamela Joy, Veronica Wiley, Meredyth Chaplin, Carly Black, Janice Fletcher, Jim McGill, Avihu Boneh, Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study The Lancet. ,vol. 369, pp. 37- 42 ,(2007) , 10.1016/S0140-6736(07)60029-4